A Phase 1 interventional study of Fludarabine and Cyclophosphamide in Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) and Colorectal Adenocarcinoma, sponsored by Neowise Biotechnology. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Neowise Biotechnology · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Adenocarcinoma of Lung with a site in China — 38 open to participants now, 41 under way, 9 of them phase 3. Adenocarcinoma of Lung · China.
Among the 88 studies in Adenocarcinoma of Lung with a site in China, this one is the 30th largest by planned enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 38 of the 40 other live ones, and was the 86th registered.
418 studies on the registry are indexed under Adenocarcinoma of Lung; 79 are open to participants now.
Browse Adenocarcinoma of Lung studies →38 of the 88 studies in Adenocarcinoma of Lung with a site in China are open now. Recruiting first, the newest first:
Guangdong Association of Clinical Trials · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18+
Pfizer · Sites in China, United States, Canada and 3 more countries
Ages 18+
Sun Yat-Sen University Cancer Center · Sites in China
Ages 18+
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 58 Adenocarcinoma of Lung studies recruiting now, 36 (62%) set no upper age limit and 10 (17%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 29 · Phase 3 11 · Phase 4 1
First in 2009; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 66 is close to the median of 60 across 293 interventional studies indexed under Adenocarcinoma of Lung.
Median enrollment 69 across the 57 interventional studies, 500 across the 31 observational. Of the 26 that completed or were terminated, 4 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 88 have an industry lead sponsor. The 10 most frequent:
Neowise Biotechnology is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Neowise Biotechnology has 1 study filed under Adenocarcinoma of Lung — fewer than ten, so there is no comparison to draw.
7 of the studies in Adenocarcinoma of Lung with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06634966Phase 3Fudan UniversitySegmentectomy for Solid-dominant Lung Cancer | 2026-12-31 |
| NCT06730477Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyPlasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma | 2026-12-30 |
| NCT05191485Sichuan Cancer Hospital and Research InstituteShared Decision Making in Patients With Lung Cancer | 2026-12-31 |
| NCT07647692Peking University People's HospitalDeep Learning Time-Series Prediction of Long-Term Growth Patterns of Pulmonary Ground-Glass Nodules Using Serial CT | 2027-06-01 |
| NCT06528847Shanghai Pulmonary Hospital, Shanghai, ChinaAdjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 88 studies in Adenocarcinoma of Lung with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-arm, multicenter, open-label, Phase 1a/1b dose-escalation and dose-expansion study designed to evaluate the safety, preliminary antitumor activity, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of NW-301V, an autologous TCR-T cell therapy, in Chinese adult participants with advanced malignant solid tumors harboring a KRAS G12V mutation.
There are 2 parts in this study:
Participants who meet the protocol-defined eligibility criteria during screening will undergo leukapheresis for the manufacture of NW-301V. Prior to NW-301V infusion, participants will receive a lymphodepletion (LD) regimen consisting of fludarabine and cyclophosphamide. Participants will be closely monitored for safety, tolerability and treatment response throughout the study.
Key Inclusion Criteria:
Applicable to both Phase 1a and 1b:
For Phase 1a only:
For Phase 1b only:
(Additional protocol-defined Inclusion criteria may apply)
Key Exclusion Criteria:
Applicable to both Phase 1a and 1b:
(Additional protocol-defined Inclusion criteria may apply)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive lymphodepletion and a single infusion of NW-301V, an autologous TCR-T cell therapy targeting KRAS G12V. In Phase 1a (dose escalation), two dose levels at 4×10\^9 (±30%) and 8×10\^9 (±30%) TCR-T+ cells will be tested. In Phase 1b (dose expansion), NW-301V will be administered at provisional RP2D in 3 tumor-specific cohorts (Cohort A: pancreatic ductal adenocarcinoma; Cohort B: colorectal adenocarcinoma; Cohort C: lung adenocarcinoma), each containing around 20 participants.
Drug: Fludarabine · Drug: Cyclophosphamide · Biological: NW-301V
Used for lymphodepletion
Used for lymphodepletion
NW-301V is an autologous TCR-T cell therapy targeting KRAS G12V in the context of HLA-A\*11:01, administered intravenously after lymphodepletion.
Phase 1a: Safety and tolerability of NW-301V in participants with advanced solid tumors
Type, frequency, and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), abnormalities in vital signs, electrocardiograms (ECGs) and other laboratory results.
Time frame: Through the study completion, an average of 2 years
Phase 1a: Maximum tolerated dose (MTD, if applicable) and provisional Recommended Phase 2 Dose (RP2D)
Number of participants with dose-limiting toxicities (DLTs) and their types.
Time frame: 28 days
Phase 1b: Safety and tolerability of NW-301V in PDAC, CRC and LUAD respectively under provisional RP2D
Type, frequency, and severity of TEAEs, SAEs, and abnormalities in vital signs, ECGs and other laboratory results.
Time frame: Through the study completion, an average of 2 years
Phase 1b: Final RP2D of NW-301V
Determine the final RP2D of NW-301V
Time frame: Up to 2 years
Objective response rate (ORR)
Assessed by RECIST v1.1. (Phase 1a: in the entire cohort; Phase 1b: in PDAC, CRC and LUAD respectively)
Time frame: Through the study completion, an average of 2 years
Disease control rate (DCR)
Assessed by RECIST v1.1. (Phase 1a: in the entire cohort; Phase 1b: in PDAC, CRC and LUAD respectively)
Time frame: Through the study completion, an average of 2 years
Duration of response (DOR)
Assessed by RECIST v1.1. (Phase 1a: in the entire cohort; Phase 1b: in PDAC, CRC and LUAD respectively)
Time frame: Through the study completion, an average of 2 years
Progression-free survival (PFS)
Assessed by RECIST v1.1. (Phase 1a: in the entire cohort; Phase 1b: in PDAC, CRC and LUAD respectively)
Time frame: Through the study completion, an average of 2 years
Overall survival (OS)
(Phase 1a: in the entire cohort; Phase 1b: in PDAC, CRC and LUAD respectively)
Time frame: Through the study completion, an average of 2 years
Maximum blood concentration (Cmax) of NW-301V
Time frame: Through the study completion, an average of 2 years
Time to maximum concentration (Tmax) of NW-301V
Time frame: Through the study completion, an average of 2 years
Persistence of NW-301V TCR-T cells in vivo
Determined by qPCR-measured gene copies
Time frame: Through the study completion, an average of 2 years
Start is estimated for Oct 2026; primary completion for Mar 2030, 41 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NW-301V
Neowise Biotechnology